Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study

Open access
Iyer, Prashanth G., Peden, Marc C., Suñer, Ivan J., Patel, Nish, Dubovy, Sander R., Albini, Thomas A.·2020·American Journal of Ophthalmology Case Reports

Abstract

PURPOSE: To describe the clinical and pathologic characteristics of a case of retinal vasculitis and vitritis following brolucizumab administration and subsequent ranibizumab treatment. OBSERVATIONS: A 76-year old Caucasian woman experienced pain, decreased vision and floaters one week after receiving her third monthly intravitreal brolucizumab injection in the right eye for exudative age-related macular degeneration. Examination was significant for 0.5+ anterior chamber cells, vitritis, mild peripheral vascular sheathing, and decreased vision from 20/70 to 20/200. She was started on topical 1% prednisolone acetate with improvement in her examination. She was switched to ranibizumab one month after her last brolucizumab injection of the right eye. Three weeks after her ranibizumab injection, she noticed photophobia, pain and decreased vision. Examination revealed worsening uveitis, vitritis, vascular sheathing, and decreased vision to count fingers. Despite starting on 0.05% difluprednate drops every 2 hours and oral high-dose methylprednisolone, the patient did not have any significant improvement in her symptoms or examination. She underwent pars plana vitrectomy and vitreous biopsy with intravitreal triamcinolone injection to the right eye. Vitreous biopsy and culture ruled out infectious endophthalmitis, and further cytopathologic analysis revealed chronic inflammatory infiltrate. CONCLUSION AND IMPORTANCE: Treatment with brolucizumab can result in intraocular inflammation and retinal vasculitis likely due to a delayed hypersensitivity reaction to the drug, supported by cytopathologic analysis of a vitreous sample. We demonstrate a case where retreatment with an alternative anti-VEGF agent resulted in worsening vision and vasculitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajoc.2020.100989

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 (A) Fundus photograph of the right eye one week after the 3rd injection of brolucizumab. Near the disc there are areas of retinal whitening (white arrow). Plaques with associated sheathing are present in the superotemporal artery (yellow boxes). In addition, in the periphery there is boxcarring of the vessels (blue arrow). Multiple vitreous debris was also seen (green arrows). Optical coherence tomography insert demonstrates a large pigment epithelial detachment with subretinal fluid. (B) Fundus photography of the right eye 21 days after treatment with ranibizumab. Fundus has significant debris and haze (green arrow), worsening retinal whitening (white arrow), vascular sheathing nasal to disc (black arrow), and persistent boxcarring of the vessels. Optical coherence tomography insert reveals a collapsed pigment epithelial detachment with retinal atrophy and resolution of the subretinal fluid. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 1 (A) Fundus photograph of the right eye one week after the 3rd injection of brolucizumab. Near the disc there are areas of retinal whitening (white arrow). Plaques with associated sheathing are present in the superotemporal artery (yellow boxes). In addition, in the periphery there is boxcarring of the vessels (blue arrow). Multiple vitreous debris was also seen (green arrows). Optical coherence tomography insert demonstrates a large pigment epithelial detachment with subretinal fluid. (B) Fundus photography of the right eye 21 days after treatment with ranibizumab. Fundus has significant debris and haze (green arrow), worsening retinal whitening (white arrow), vascular sheathing nasal to disc (black arrow), and persistent boxcarring of the vessels. Optical coherence tomography insert reveals a collapsed pigment epithelial detachment with retinal atrophy and resolution of the subretinal fluid. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)CC BY-NC-ND · PubMed Central
Fig. 2 (A) Pre-operative image reveals vitreous debris. (B) Post-operative image from day 1 status post pars plana vitrectomy, vitreous biopsy and intravitreal triamcinolone of the right eye (green arrow). Persistent sheathing, plaques and boxcarring of the vessels (blue arrows) is present (C) Early fluorescein angiography had delayed perfusion of both veins and arteries. Mid- and late-phase fluorescein angiography showed vessel boxcarring (D) and late disc leakage (E). (F) Fundus photograph two weeks status post pars plana vitrectomy demonstrates new plaques (yellow boxes), persistent boxcarring (blue arrows), macular hemorrhage (black arrow) and resolution of vitritis. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2 (A) Pre-operative image reveals vitreous debris. (B) Post-operative image from day 1 status post pars plana vitrectomy, vitreous biopsy and intravitreal triamcinolone of the right eye (green arrow). Persistent sheathing, plaques and boxcarring of the vessels (blue arrows) is present (C) Early fluorescein angiography had delayed perfusion of both veins and arteries. Mid- and late-phase fluorescein angiography showed vessel boxcarring (D) and late disc leakage (E). (F) Fundus photograph two weeks status post pars plana vitrectomy demonstrates new plaques (yellow boxes), persistent boxcarring (blue arrows), macular hemorrhage (black arrow) and resolution of vitritis. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)CC BY-NC-ND · PubMed Central
Fig. 3 Cytopathology of the vitreous biopsy: (A) Cytospin vitreous sample demonstrates lymphocytes (black arrow) and vitreous strands (asterisk) (PAP, original magnification ×400). (B) Rare CD20 positive B-cells are present (black arrow) (CD20, original magnification ×400). (C) Many CD3 positive T-cells are present (black arrows) (CD3, original magnification ×400). (D) Few CD4 positive T-helper cells are present (black arrow) (CD4, original magnification ×400). (E) A moderate number of CD8 positive T-cytotoxic cells are present (black arrows) (CD8, original magnification ×400). (F) CD68 positive histiocytes (black arrow) are present with foci of vitreous strands (asterisk) (CD68, original magnification ×400).
Fig. 3 Cytopathology of the vitreous biopsy: (A) Cytospin vitreous sample demonstrates lymphocytes (black arrow) and vitreous strands (asterisk) (PAP, original magnification ×400). (B) Rare CD20 positive B-cells are present (black arrow) (CD20, original magnification ×400). (C) Many CD3 positive T-cells are present (black arrows) (CD3, original magnification ×400). (D) Few CD4 positive T-helper cells are present (black arrow) (CD4, original magnification ×400). (E) A moderate number of CD8 positive T-cytotoxic cells are present (black arrows) (CD8, original magnification ×400). (F) CD68 positive histiocytes (black arrow) are present with foci of vitreous strands (asterisk) (CD68, original magnification ×400).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 1

  1. Novartis. Novartis Provides Update on Use and Safety of Beovu (Brolucizumab). April vol. 28, 2020.

Cited by

See all 60

Metadata

Authors
Iyer, P. G., Peden, M. C., Suñer, I. J., Patel, N., Dubovy, S. R., & Albini, T. A.
Affiliations
Retina Associates of Florida (US)
Corresponding author
Albini, Thomas A.
Venue
American Journal of Ophthalmology Case Reports
Publisher
Elsevier BV
Published
2020-12
Volume
20
Pages
100989
ISSN
2451-9936 (ISSN-L)
OpenAlex
W3101908837
Cited by
60
References
25
Citations by year
2026: 2 · 2025: 5 · 2024: 16 · 2023: 8 · 2022: 11 · 2021: 17
FWCI
7.14
Type
journal article
Language
en
Open access
Licence
Locations
  • American Journal of Ophthalmology Case Reports (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Minnesota Lions Eye Bank
Topics
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
Keywords
brolucizumab, ranibizumab, retinal vasculitis, vitritis, uveitis, anti-VEGF therapy adverse effects, drug hypersensitivity, neovascular age-related macular degeneration, vitreous biopsy, vitrectomy, intravitreal triamcinolone acetonide, corticosteroid therapy, retreatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study. https://app.cochat.ai/papers/10.1016/j.ajoc.2020.100989
The paper
Iyer, P. G., Peden, M. C., Suñer, I. J., Patel, N., Dubovy, S. R., & Albini, T. A. (2020). Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study. American Journal of Ophthalmology Case Reports. https://doi.org/10.1016/j.ajoc.2020.100989

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.